Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Renewal of Intestinal Stem Cells

Renewal of Intestinal Stem Cells

The intestinal epithelial lining rapidly renews every 4 to 5 days. The renewal is facilitated by intestinal stem cells (ISCs) located at the base of the crypt– a gland located at the bottom of each villus. ISCs divide asymmetrically to form new stem cells and progenitor daughter cells. The daughter cells are called transit-amplifying (TA) cells which move upwards along the crypt and either differentiate into absorptive cells– the enterocytes or secretory cells– including the...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Corrigendum to "Oleanolic acid 28-O-β-D-glucopyranoside alleviates TNBS-induced ulcerative colitis in rat by regulating Nrf2/x-CT/GPX4-mediated ferroptosis" [Journal of Ethnopharmacology 353 (2025) 120369].

Journal of ethnopharmacology·2026

Same author

Targeting barrier integrity: Pseudoginsenoside RT2 ameliorates ulcerative colitis by driving epithelial renewal via the Wnt/β-catenin pathway.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2026

Same author

Elevating RNA m<sup>5</sup>C methylation provides a promising strategy for crop productivity.

National science review·2026

Same author

Research landscape, knowledge structure, and emerging frontiers of robot-assisted surgery for urolithiasis: a bibliometric and visualization analysis.

Journal of robotic surgery·2026

Same author

Laparoendoscopic single-site versus conventional laparoscopic living donor nephrectomy: a systematic review and meta-analysis of randomized controlled trials.

International urology and nephrology·2026

Same author

Multi-omics integration maps CHH methylation and gene regulatory networks across heat, drought, and salt stress in rice.

Cell reports·2026

Search research articles

Related Experiment Video

Updated: Jan 17, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

Ginsenoside Rk2 Provides Multidimensional Relief for Ulcerative Colitis by Improving Intestinal Barrier Function,

Luying Tan¹, Zhuoqiao Li¹, Junzhe Wu¹

¹School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.

Journal of Agricultural and Food Chemistry

|September 25, 2025

Summary

This summary is machine-generated.

Ginsenoside Rk2 (Rk2) shows promise in treating ulcerative colitis (UC) by improving gut barrier function, microbiota, and immune balance. This natural compound offers a potential therapeutic approach for managing UC symptoms and inflammation.

Keywords:

Th17/Treg balance ginsenoside Rk2 gut microbiota intestinal barrier function ulcerative colitis

More Related Videos

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Related Experiment Videos

Last Updated: Jan 17, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Area of Science:

Gastroenterology
Immunology
Pharmacology

Background:

Ulcerative colitis (UC) is a complex inflammatory bowel disease impacting intestinal barrier integrity, gut microbiota, and immune homeostasis.
Ginsenoside Rk2 (Rk2) has previously shown anti-inflammatory properties in cellular models.

Purpose of the Study:

To investigate the therapeutic effects of Rk2 on UC by examining its impact on the "barrier-microbiota-immune" axis.
To elucidate the potential molecular pathways involved in Rk2's action in UC.

Main Methods:

Assessed Rk2's effects on inflammatory markers and colitis symptoms.
Measured intestinal epithelial barrier function using transepithelial electrical resistance (TEER) and tight junction protein expression.
Analyzed gut microbiota composition and short-chain fatty acids (SCFAs) levels.
Evaluated immune cell balance (Th17/Treg) and investigated the TNFSF14/LTβR/NIK pathway.

Main Results:

Rk2 improved inflammatory factor levels and colitis symptoms.
Rk2 enhanced intestinal barrier function by increasing TEER and tight junction protein expression.
Rk2 positively remodeled gut microbiota diversity and SCFA levels, and restored Th17/Treg balance.
Rk2's effects may involve the TNFSF14/LTβR/NIK pathway.

Conclusions:

Rk2 demonstrates multidimensional therapeutic benefits for UC by regulating the "barrier-microbiota-immune" axis.
Rk2 presents potential as a natural therapeutic agent for ulcerative colitis.